Erlotinib

Abdelgalil, Ahmed A.; Alkahtani, Hamad M.; Al-Jenoobi, Fahad I.

doi:10.1016/bs.podrm.2019.10.004

Cited by 69 publications

(39 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Accrding to previous reports, patients of all age groups ranged from several months to 78 years old, especially children and young adults [12]. The most common clinical symptom was cough [13].…”

Section: Discussionmentioning

confidence: 54%

NUT Midline Carcinoma as a Primary Lung Tumor Treated With Anlotinib Combined With Palliative Radiotherapy: a Case Report

Jen¹,

Ren²,

Xu³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: NUT (nuclear protein in testis) midline carcinoma (NMC) is a rapidly progressive tumor arising from midline structures. Recent cases have reported that the poor prognosis with a median survival of 6.7 months and a 2 years overall survival of 19% due to limited treatment. Based on the effect of arotinib on inhibiting tumor growth and angiogenesis. We present one patient case treated with anlotinib and radiotherapy.Case presentation: Here, we describe a 33-year old patient who complained of cough and chest pain and was diagnosed as a pulmonary NMC through CT scan, FISH and immunohistochemistry. In addition, we initially demonstrated that anlotinib combined with palliative radiotherapy could significantly prevent the tumor growth in a pulmonary NMC.Conclusion: The report indicated that anlotinib combined with palliative radiotherapy could inhibit the tumor progression in a pulmonary NMC, which may provide a combined therapy to pulmonary NMC in the future.

show abstract

Section: Discussionmentioning

confidence: 54%

NUT Midline Carcinoma as a Primary Lung Tumor Treated With Anlotinib Combined With Palliative Radiotherapy: a Case Report

Jen¹,

Ren²,

Xu³

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…The largest centralized report is a retrospective analysis published in the Journal of Thoracic Cancer in 2015 [ 14 ], a review of the study The clinical features of 8 cases of lung NUT cancer were analyzed. Unfortunately, the average survival time of 8 patients was only 2.2 months, which was much lower than the 5.5-month average survival time of 119 cases of NUT cancer reported by Giridha [ 15 ]. It was unfortunate that most patients had lose the surgery chance because of its distant metastases.…”

Section: Discussionmentioning

confidence: 66%

“…Even so, there is no standard treatment to NMC. We noted that the majority of patients were administrated chemotherapy and/or radiotherapy [ 15 ]. Here, for the first time we revealed that the primary pulmonary NMC, initially treated with the combination of radiotherapy and anlotinib for antiangiogenesis.…”

Section: Discussionmentioning

confidence: 99%

NUT midline carcinoma as a primary lung tumor treated with anlotinib combined with palliative radiotherapy: a case report

Jiang

Ren

et al. 2022

Diagn Pathol

View full text Add to dashboard Cite

Background NUT (nuclear protein in testis) midline carcinoma (NMC) is a rapidly progressive tumor arising from midline structures. Recent cases have reported that the poor prognosis with a median survival of 6.7 months and a 2 years overall survival of 19% due to limited treatment. Based on the effect of arotinib on inhibiting tumor growth and angiogenesis. We present one patient case treated with anlotinib and radiotherapy. Case presentation Here, we describe a 33-year old patient who complained of cough and chest pain and was diagnosed as a pulmonary NMC through CT scan, FISH and immunohistochemistry. In addition, we initially demonstrated that anlotinib combined with palliative radiotherapy could significantly prevent the tumor growth in a pulmonary NMC. Conclusion The report indicated that anlotinib combined with palliative radiotherapy could inhibit the tumor progression in a pulmonary NMC, which may provide a combined therapy to pulmonary NMC in the future.

show abstract

“…These kinases are involved in a broad range of cellular functions, and therefore they are related to different diseases such as cancer or Parkinson’s disease. 42 In fact, there are kinase inhibitors approved for the treatment of different cancers, such as sunitinib 43 ( 2 ) or erlotinib ( 3 ), 44 and baricitinib 45 ( 4 ) for the treatment of rheumatoid arthritis ( Figure 1 ). Also the physiological function of these enzymes has been also related to the regulation of intracellular membrane trafficking.…”

Section: Numb-associated Kinases (Naks)mentioning

confidence: 99%

Kinase Inhibitors as Underexplored Antiviral Agents

et al. 2021

View full text Add to dashboard Cite

Viral infections are a major health problem; therefore, there is an urgent need for novel therapeutic strategies. Antivirals used to target proteins encoded by the viral genome usually enhance drug resistance generated by the virus. A potential solution may be drugs acting at host-based targets since viruses are dependent on numerous cellular proteins and phosphorylation events that are crucial during their life cycle. Repurposing existing kinase inhibitors as antiviral agents would help in the cost and effectiveness of the process, but this strategy usually does not provide much improvement, and specific medicinal chemistry programs are needed in the field. Anyway, extensive use of FDA-approved kinase inhibitors has been quite useful in deciphering the role of host kinases in viral infection. The present perspective aims to review the state of the art of kinase inhibitors that target viral infections in different development stages.

show abstract

Erlotinib

Cited by 69 publications

References 33 publications

NUT Midline Carcinoma as a Primary Lung Tumor Treated With Anlotinib Combined With Palliative Radiotherapy: a Case Report

NUT Midline Carcinoma as a Primary Lung Tumor Treated With Anlotinib Combined With Palliative Radiotherapy: a Case Report

NUT midline carcinoma as a primary lung tumor treated with anlotinib combined with palliative radiotherapy: a case report

Kinase Inhibitors as Underexplored Antiviral Agents

Contact Info

Product

Resources

About